ImmunityBio officer proposes $7.66M share sale

The proposed sale names The Charles Schwab Corporation as broker and NASDAQ as the exchange.

Rhea-AI Filing Summary

ImmunityBio, Inc. (IBRX) reported a proposed sale by officer and director Barry J. Simon of 560,000 common shares, with an aggregate market value of $7,657,760.00 and an approximate sale date of October 5, 2026. The reported securities are listed with an open-market transaction dated December 31, 2013.

Key Figures

Common shares proposed for sale: 560,000 shares Aggregate market value: $7,657,760.00 Approximate sale date: October 5, 2026

3 metrics

Common shares proposed for sale 560,000 shares Proposed sale

Aggregate market value $7,657,760.00 Proposed sale

Approximate sale date October 5, 2026 Proposed common-share sale

Key Terms

Rule 144, person, OPEN MARKET

3 terms

Rule 144 regulatory

"paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

person regulatory

"definition of "person" in paragraph (a) of Rule 144"

OPEN MARKET financial

"12/31/2013 | OPEN MARKET | ISSUER"

An open market is a system where buying and selling of goods, services, or financial assets happen freely without restrictions or special controls. For investors, it means they can trade assets easily and quickly, which helps determine fair prices based on supply and demand. This environment encourages transparency and competition, making it easier to buy or sell with confidence.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many IBRX shares does Barry J. Simon propose to sell?

Barry J. Simon is listed for a proposed sale of 560,000 common shares, with an aggregate market value of $7,657,760.00 and an approximate sale date of October 5, 2026.

Which broker and exchange are listed for Barry J. Simon's IBRX sale?

The proposed sale names The Charles Schwab Corporation as broker and NASDAQ as the exchange.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/05/2026 - 10:22 AM Accepted by SEC EDGAR 10/05/2026 - 10:21 AM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001647994
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ImmunityBio, Inc.
SEC File Number	001-37507
Address of Issuer	3530 JOHN HOPKINS COURT SAN DIEGO CALIFORNIA 92121
Phone	(844) 696-5235
Name of Person for Whose Account the Securities are To Be Sold	Simon Barry J.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
COMMON	THE CHARLES SCHWAB CORPORATION 3000 Schwab Way Westlake TX 76262	560000	7657760.00	1059836273	10/05/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
COMMON	12/31/2013	OPEN MARKET	ISSUER			560000	12/31/2013	NA

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	10/05/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/18/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	BARRY J. SIMON
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)